Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer

Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer is a phase 2, interventional study registered as NCT07214142 by The First Affiliated Hospital of University of Science and Technology of China, with a registry enrolment figure of 30 participants, started 2025-10-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: PD-1. Conditions listed: Rectal Cancer Patients. Primary outcome: pathological complete response rate. Colorectal eligibility wording from the registry: "Pathologically confirmed rectal adenocarcinoma;". No results are recorded here; the registry entry is the source.